NICE recommends Briumvi for RRMS
Germany-headquartered CNS drug specialist Neuraxpharm today revealed that UK health technology assessor the National Institute for Health and Care Excellence (NICE) has issued a positive recommendation for the use of ublituximab (150mg concentrate for solution for infusion) in the treatment of relapsing-remitting multiple sclerosis (RRMS).
.Ublituximab, trade named Briumvi, developed by TG Therapeutics (Nasdaq: TGTX) and licensed by Neuraxpharm ex-US, is a type of protein called a monoclonal antibody that selectively targets CD-20-expressing cells. It is the first and only anti-CD20 monoclonal antibody approved in the USA and European Union (EU) for adult patients with RRMS that can be administered in a one-hour infusion, twice a year, following the starting dose.2,5,6
Clinical backing
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze